Search
Atopic Dermatitis Clinical Trials in Quincy, MA
A listing of 4 Atopic Dermatitis clinical trials in Quincy, MA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 4 of 4
The city of Quincy, Massachusetts, currently has 4 active clinical trials seeking participants for Atopic Dermatitis research studies.
Featured Trial
Eczema Clinical Trial for Children & Adolsecents
Recruiting
Enrolling candidates diagnosed with Atopic Dermatitis (Eczema). Compensation available.
Conditions:
Atopic Dermatitis
Eczema
Atopic Dermatitis Eczema
Dermatitis
Atopic
Featured Trial
Eczema Clinical Study
Recruiting
The purpose of this clinical study is to see whether an oral investigational medication can help to treat symptoms of moderate to severe Atopic Dermatitis (eczema).
Conditions:
Eczema
Atopic Dermatitis Eczema
Atopic Eczema
Eczema
Atopic
* Compensation for time may be available
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: Integrated Dermatology of Massachusetts, Quincy, Massachusetts
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
Recruiting
This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Inno-6050 Site 16, Quincy, Massachusetts
Conditions: Atopic Dermatitis
POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis
Recruiting
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections, as monotherapy or as add-on therapy with dupilumab.
The study will enroll patients with moderate to severe AD in 4 cohorts. There will be 2 Monotherapy Cohorts, assigned to different doses of BSI-045B: a 300 mg Cohort and a 480 mg Cohort. There will be 2 Add-on Therapy Cohorts, assigned to different... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/30/2024
Locations: Beacon Clinical Research, Quincy, Massachusetts
Conditions: Atopic Dermatitis
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Quincy, Massachusetts
Conditions: Atopic Dermatitis
1 - 4 of 4